Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

Pharmacokinetic profile of dolutegravir after transjugular intrahepatic portosystemic shunt placement.

Fabbiani M, Cattaneo D, Lombardi A, Colaneri M, Sambo M, Novati S, Fusi M, Bruno R.

J Antimicrob Chemother. 2020 Jan 24. pii: dkz572. doi: 10.1093/jac/dkz572. [Epub ahead of print] No abstract available.

PMID:
31976524
2.

Determination of pentraxin 3 levels in cerebrospinal fluid during central nervous system infections.

Zatta M, Di Bella S, Bottazzi B, Rossi F, D'Agaro P, Segat L, Fabbiani M, Mantovani A, Luzzati R.

Eur J Clin Microbiol Infect Dis. 2019 Dec 8. doi: 10.1007/s10096-019-03767-w. [Epub ahead of print]

PMID:
31813079
3.

Cognitive impairment and cardiovascular disease related to alexithymia in a well-controlled HIV-infected population.

Ciccarelli N, Baldonero E, Milanini B, Fabbiani M, Cauda R, Di Giambenedetto S, Silveri MC.

Infez Med. 2019 Sep 1;27(3):274-282.

4.

Reduced soluble CD14 levels after switching from a dual regimen with lamivudine plus boosted protease inhibitors to lamivudine plus dolutegravir in virologically suppressed HIV-infected patients.

Lombardi F, Belmonti S, Borghetti A, Ciccullo A, Baldin G, Cauda R, Fabbiani M, Di Giambenedetto S.

HIV Res Clin Pract. 2019 Sep 3:1-7. doi: 10.1080/25787489.2019.1653512. [Epub ahead of print]

PMID:
31478469
5.

The Case of Formic Acid on Anatase TiO2 (101): Where is the Acid Proton?

Tabacchi G, Fabbiani M, Mino L, Martra G, Fois E.

Angew Chem Int Ed Engl. 2019 Sep 2;58(36):12431-12434. doi: 10.1002/anie.201906709. Epub 2019 Aug 7.

PMID:
31310450
6.

Hepatitis C virus-related factors associated WITH cognitive performance in HIV-HCV-coinfected patients.

Fabbiani M, Ciccarelli N, Castelli V, Soria A, Borghetti A, Colella E, Moschese D, Valsecchi M, Emiliozzi A, Gori A, De Luca A, Bandera A, Di Giambenedetto S.

J Neurovirol. 2019 Dec;25(6):866-873. doi: 10.1007/s13365-019-00780-9. Epub 2019 Jul 7.

PMID:
31281946
7.

Impact of genotypic susceptibility score on cART outcomes during primary HIV infection.

Giacomelli A, Fabbiani M, De Benedetto I, Nozza S, Focà E, Celesia BM, Marchetti G, Mussini C, Antinori A, d'Ettorre G, Madeddu G, Bandera A, Muscatello A, Rusconi S.

J Med Virol. 2019 Oct;91(10):1891-1895. doi: 10.1002/jmv.25517. Epub 2019 Jun 27.

PMID:
31199538
8.

The impact of HIV infection and men who have sex with men status on hepatitis A infection: The experience of two tertiary centres in Northern Italy during the 2017 outbreak and in the 2009-2016 period.

Lombardi A, Rossotti R, Moioli MC, Merli M, Valsecchi P, Zuccaro V, Vecchia M, Grecchi C, Patruno SFA, Sacchi P, Fabbiani M, Puoti M, Bruno R.

J Viral Hepat. 2019 Jun;26(6):761-765. doi: 10.1111/jvh.13082. Epub 2019 Mar 25.

PMID:
30801838
9.

Liver fibrosis is associated with cognitive impairment in people living with HIV.

Ciccarelli N, Fabbiani M, Brita AC, De Marco R, Grima P, Gagliardini R, Borghetti A, Cauda R, Di Giambenedetto S.

Infection. 2019 Aug;47(4):589-593. doi: 10.1007/s15010-019-01284-8. Epub 2019 Feb 19.

PMID:
30784024
10.

Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial.

Fabbiani M, Gagliardini R, Ciccarelli N, Quiros Roldan E, Latini A, d'Ettorre G, Antinori A, Castagna A, Orofino G, Francisci D, Chinello P, Madeddu G, Grima P, Rusconi S, Del Pin B, Lombardi F, D'Avino A, Focà E, Colafigli M, Cauda R, Di Giambenedetto S, De Luca A; ATLAS-M Study Group.

J Antimicrob Chemother. 2018 Jul 1;73(7):1955-1964. doi: 10.1093/jac/dky123.

PMID:
29668978
11.

The NLRP3 Inflammasome Is Upregulated in HIV-Infected Antiretroviral Therapy-Treated Individuals with Defective Immune Recovery.

Bandera A, Masetti M, Fabbiani M, Biasin M, Muscatello A, Squillace N, Clerici M, Gori A, Trabattoni D.

Front Immunol. 2018 Feb 12;9:214. doi: 10.3389/fimmu.2018.00214. eCollection 2018.

12.

Does the Abiotic Formation of Oligopeptides on TiO₂ Nanoparticles Require Special Catalytic Sites? Apparently Not.

Fabbiani M, Pazzi M, Vincenti M, Tabacch G, Fois E, Martra G.

J Nanosci Nanotechnol. 2018 Aug 1;18(8):5854-5857. doi: 10.1166/jnn.2018.15385.

PMID:
29458653
13.

Higher Levels of Peripheral Th17 T CD4+ Cells Are Associated With Immunological Non Response in HIV-Infected Patients Under Effective ART.

De Benedetto I, Masetti M, Fabbiani M, Biasin M, Muscatello A, Squillace N, Clerici M, Trabattoni D, Gori A, Bandera A.

J Acquir Immune Defic Syndr. 2018 Apr 15;77(5):e45-e47. doi: 10.1097/QAI.0000000000001627. No abstract available.

PMID:
29315114
14.

Reply.

Soria A, Lapadula G, Fabbiani M, Gori A.

Hepatology. 2018 Mar;67(3):1182-1183. doi: 10.1002/hep.29700. Epub 2018 Jan 30. No abstract available.

PMID:
29194724
15.

Update of the budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial.

Restelli U, Fabbiani M, Di Giambenedetto S, Nappi C, Croce D.

Clinicoecon Outcomes Res. 2017 Sep 27;9:569-571. doi: 10.2147/CEOR.S143377. eCollection 2017. No abstract available.

16.

Reply.

Soria A, Lapadula G, Fabbiani M, Gori A.

Hepatology. 2017 Dec;66(6):2091-2092. doi: 10.1002/hep.29553. Epub 2017 Nov 6. No abstract available.

PMID:
28960411
17.

Brief Report: Peripheral Monocyte/Macrophage Phenotypes Associated With the Evolution of Cognitive Performance in HIV-Infected Patients.

Fabbiani M, Muscatello A, Perseghin P, Bani M, Incontri A, Squillace N, Lapadula G, Gori A, Bandera A.

J Acquir Immune Defic Syndr. 2017 Oct 1;76(2):219-224. doi: 10.1097/QAI.0000000000001480.

PMID:
28902679
18.

3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir.

Gagliardini R, Bandera A, Zaccarelli M, Sterrantino G, Latini A, D'Avino A, Lapadula G, Antinori A, Cauda R, De Luca A, Gori A, Di Giambenedetto S, Fabbiani M.

Antivir Ther. 2018;23(2):139-148. doi: 10.3851/IMP3188.

PMID:
28799920
19.

Unexpected viral relapses in hepatitis C virus-infected patients diagnosed with hepatocellular carcinoma during treatment with direct-acting antivirals.

Soria A, Fabbiani M, Lapadula G, Gori A.

Hepatology. 2017 Sep;66(3):992-994. doi: 10.1002/hep.29181. Epub 2017 Jul 18. No abstract available.

PMID:
28370176
20.

Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial.

Lombardi F, Belmonti S, Quiros-Roldan E, Latini A, Castagna A, D'Ettorre G, Gagliardini R, Fabbiani M, Cauda R, De Luca A, Di Giambenedetto S; AtLaS-M Study Group.

J Antimicrob Chemother. 2017 Jul 1;72(7):2055-2059. doi: 10.1093/jac/dkx068.

PMID:
28333353
21.
22.

Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M).

Di Giambenedetto S, Fabbiani M, Quiros Roldan E, Latini A, D'Ettorre G, Antinori A, Castagna A, Orofino G, Francisci D, Chinello P, Madeddu G, Grima P, Rusconi S, Di Pietro M, Mondi A, Ciccarelli N, Borghetti A, Focà E, Colafigli M, De Luca A, Cauda R; Atlas-M Study Group.

J Antimicrob Chemother. 2017 Apr 1;72(4):1163-1171. doi: 10.1093/jac/dkw557.

PMID:
28093483
23.

Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients.

Gagliardini R, Fabbiani M, Colafigli M, D'Avino A, Mondi A, Borghetti A, Lamonica S, Cauda R, De Luca A, Di Giambenedetto S.

J Chemother. 2017 Oct;29(5):299-307. doi: 10.1080/1120009X.2016.1269040. Epub 2016 Dec 26.

PMID:
28019192
24.

Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients.

Fabbiani M, Di Giambenedetto S, Poli A, Borghetti A, Castagna A, Mondi A, Galizzi N, Maillard M, Gori A, Cauda R, De Luca A, Gianotti N.

J Infect. 2016 Dec;73(6):619-623. doi: 10.1016/j.jinf.2016.08.011. Epub 2016 Aug 26. No abstract available.

PMID:
27575581
25.

Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study.

Latini A, Fabbiani M, Borghi V, Sterrantino G, Giannetti A, Lorenzini P, Loiacono L, Ammassari A, Bellagamba R, Colafigli M, D'Ettorre G, Di Giambenedetto S, Antinori A, Zaccarelli M.

BMC Infect Dis. 2016 Aug 11;16(1):401. doi: 10.1186/s12879-016-1703-z.

26.

Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study.

Lombardi F, Belmonti S, Fabbiani M, Borghetti A, Cauda R, De Luca A, Di Giambenedetto S.

J Antimicrob Chemother. 2016 Dec;71(12):3621-3622. Epub 2016 Aug 3. No abstract available.

PMID:
27494930
27.

Liver fibrosis progression and clinical outcomes are intertwined: role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCV-coinfected patients with detectable HCV-RNA: A MASTER cohort study.

Focà E, Fabbiani M, Prosperi M, Quiros Roldan E, Castelli F, Maggiolo F, Di Filippo E, Di Giambenedetto S, Gagliardini R, Saracino A, Di Pietro M, Gori A, Sighinolfi L, Pan A, Postorino MC, Torti C; Italian MASTER Cohort.

Medicine (Baltimore). 2016 Jul;95(29):e4091. doi: 10.1097/MD.0000000000004091.

28.

Verbal list learning and memory profiles in HIV-infected adults, Alzheimer's disease, and Parkinson's disease: An evaluation of the "cortical hypothesis" of NeuroAIDS.

Ciccarelli N, Limiti S, Fabbiani M, Baldonero E, Milanini B, Lamonica S, Cauda R, Di Giambenedetto S, Silveri MC.

Appl Neuropsychol Adult. 2017 Sep-Oct;24(5):410-419. doi: 10.1080/23279095.2016.1189424. Epub 2016 Jun 13.

PMID:
27292092
29.

Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine versus the 23-Valent Polysaccharide Vaccine in Unvaccinated HIV-Infected Adults: A Pilot, Prospective Controlled Study.

Lombardi F, Belmonti S, Fabbiani M, Morandi M, Rossetti B, Tordini G, Cauda R, De Luca A, Di Giambenedetto S, Montagnani F.

PLoS One. 2016 Jun 3;11(6):e0156523. doi: 10.1371/journal.pone.0156523. eCollection 2016.

30.

Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE).

Milanini B, Ciccarelli N, Fabbiani M, Baldonero E, Limiti S, Gagliardini R, Borghetti A, D'Avino A, Mondi A, Colafigli M, Cauda R, Di Giambenedetto S.

Clin Neuropsychol. 2016 Jan-Dec;30(sup1):1457-1468. Epub 2016 May 16.

PMID:
27180611
31.

Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy.

Borghetti A, Baldin G, Ciccullo A, Gagliardini R, D'Avino A, Mondi A, Ciccarelli N, Lamonica S, Fanti I, Trecarichi E, Fabbiani M, Cauda R, De Luca A, Di Giambenedetto S.

J Antimicrob Chemother. 2016 Aug;71(8):2359-61. doi: 10.1093/jac/dkw147. Epub 2016 May 4. No abstract available.

PMID:
27147306
32.

Cognitive reserve and neuropsychological functioning in older HIV-infected people.

Milanini B, Ciccarelli N, Fabbiani M, Limiti S, Grima P, Rossetti B, Visconti E, Tamburrini E, Cauda R, Di Giambenedetto S.

J Neurovirol. 2016 Oct;22(5):575-583. Epub 2016 Mar 10.

PMID:
26965299
33.

Initial antifungal strategy does not correlate with mortality in patients with candidemia.

Murri R, Scoppettuolo G, Ventura G, Fabbiani M, Giovannenze F, Taccari F, Milozzi E, Posteraro B, Sanguinetti M, Cauda R, Fantoni M.

Eur J Clin Microbiol Infect Dis. 2016 Feb;35(2):187-93. doi: 10.1007/s10096-015-2527-2. Epub 2015 Dec 3.

PMID:
26634352
34.

Evaluation and Optimization of an ELISA Procedure to Quantify Antibodies Against Pneumococcal Polysaccharides Included in the 13-Valent Conjugate Vaccine.

Belmonti S, Lombardi F, Morandi M, Fabbiani M, Tordini G, Cauda R, De Luca A, Di Giambenedetto S, Montagnani F.

J Immunoassay Immunochem. 2016;37(2):189-200. doi: 10.1080/15321819.2015.1106949.

PMID:
26506438
35.

Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort).

Torti C, Raffetti E, Donato F, Castelli F, Maggiolo F, Angarano G, Mazzotta F, Gori A, Sighinolfi L, Pan A, Cauda R, Scalzini A, Quiros-Roldan E, Nasta P, Gregis G, Benatti S, Digiambenedetto S, Ladisa N, Giralda M, Saracino A, Castelnuovo F, Di Pietro M, Lo Caputo S, Lapadula G, Costarelli S, Lorenzotti S, Mazzini N, Paraninfo G, Casari S, Focà E, Pezzoli C, Fabbiani M, Monno L, Pierotti P, Ble C, Leone S, Postorino MC, Fornabaio C, Zacchi F, Zoncada A, Carosi G.

Int J Epidemiol. 2017 Apr 1;46(2):e12. doi: 10.1093/ije/dyv192. No abstract available.

PMID:
26445966
36.

Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen.

Fabbiani M, Zaccarelli M, Latini A, Sterrantino G, D'Ettorre G, Grima P, Mondi A, Rossetti B, Borchi B, Giuliani M, Antinori A, De Luca A, Di Giambenedetto S.

HIV Med. 2016 May;17(5):385-9. doi: 10.1111/hiv.12313. Epub 2015 Sep 22.

37.

Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection.

Fabbiani M, Di Giambenedetto S, Cingolani A, Fanti I, Colafigli M, Tamburrini E, Cauda R, Navarra P, De Luca A, Murri R.

Infect Dis (Lond). 2016;48(1):48-55. doi: 10.3109/23744235.2015.1082034. Epub 2015 Sep 2.

PMID:
26329383
38.

Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors.

De Luca A, Di Giambenedetto S, Lo Presti A, Sierra S, Prosperi M, Cella E, Giovanetti M, Torti C, Caudai C, Vicenti I, Saladini F, Almi P, Grima P, Blanc P, Fabbiani M, Rossetti B, Gagliardini R, Kaiser R, Ciccozzi M, Zazzi M.

Open Forum Infect Dis. 2015 Mar 31;2(2):ofv043. doi: 10.1093/ofid/ofv043. eCollection 2015 Apr.

39.

Switching to Coformulated Rilpivirine/Emtricitabine/Tenofovir in Virologically Suppressed Patients: Data From a Multicenter Cohort.

Pinnetti C, Di Giambenedetto S, Maggiolo F, Fabbiani M, Sterrantino G, Latini A, Lorenzini P, Ammassari A, Loiacono L, Bellagamba R, Boumis E, Cauda R, Antinori A, Zaccarelli M.

J Acquir Immune Defic Syndr. 2015 Dec 1;70(4):e147-50. doi: 10.1097/QAI.0000000000000727. No abstract available.

PMID:
26090757
40.

Risk of Severe Non AIDS Events Is Increased among Patients Unable to Increase their CD4+ T-Cell Counts >200+/μl Despite Effective HAART.

Lapadula G, Chatenoud L, Gori A, Castelli F, Di Giambenedetto S, Fabbiani M, Maggiolo F, Focà E, Ladisa N, Sighinolfi L, Di Pietro M, Pan A, Torti C; Italian MASTER Cohort.

PLoS One. 2015 May 28;10(5):e0124741. doi: 10.1371/journal.pone.0124741. eCollection 2015.

41.

Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study.

Mondi A, Fabbiani M, Ciccarelli N, Colafigli M, D'Avino A, Borghetti A, Gagliardini R, Cauda R, De Luca A, Di Giambenedetto S.

J Antimicrob Chemother. 2015;70(6):1843-9. doi: 10.1093/jac/dkv037. Epub 2015 Feb 26.

PMID:
25885326
42.

Cancer incidence and mortality for all causes in HIV-infected patients over a quarter century: a multicentre cohort study.

Raffetti E, Albini L, Gotti D, Segala D, Maggiolo F, di Filippo E, Saracino A, Ladisa N, Lapadula G, Fornabaio C, Castelnuovo F, Casari S, Fabbiani M, Pierotti P, Donato F, Quiros-Roldan E; MASTER Cohort.

BMC Public Health. 2015 Mar 12;15:235. doi: 10.1186/s12889-015-1565-0.

43.

Resource-saving advice from an infectious diseases specialist team in a large university hospital: an exportable model?

Fantoni M, Murri R, Scoppettuolo G, Fabbiani M, Ventura G, Losito R, Berloco F, Spanu T, Sanguinetti M, Cauda R.

Future Microbiol. 2015;10(1):15-20. doi: 10.2217/fmb.14.99.

PMID:
25598334
44.

Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility.

Fabbiani M, Grima P, Milanini B, Mondi A, Baldonero E, Ciccarelli N, Cauda R, Silveri MC, De Luca A, Di Giambenedetto S.

Antivir Ther. 2015;20(4):441-7. doi: 10.3851/IMP2926. Epub 2014 Dec 17.

PMID:
25516553
45.

Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients.

Ciccarelli N, Grima P, Fabbiani M, Baldonero E, Borghetti A, Milanini B, Limiti S, Colafigli M, Tamburrini E, Cauda R, De Luca A, Di Giambenedetto S.

Antivir Ther. 2015;20(4):433-40. doi: 10.3851/IMP2925. Epub 2014 Dec 11.

PMID:
25504667
46.

Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre.

Borghetti A, Mondi A, Piccoli B, Gagliardini R, Lamonica S, Ciccarelli N, D'Avino A, Pallavicini F, Cauda R, De Luca A, Fabbiani M, Di Giambenedetto S.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19817. doi: 10.7448/IAS.17.4.19817. eCollection 2014.

47.

Simplification to co-formulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort.

Pinnetti C, Di Giambenedetto S, Maggiolo F, Lorenzini P, Fabbiani M, Tommasi C, Latini A, Ammassari A, Loiacono L, Sterrantino G, Bellagamba R, Boumis E, Antinori A, Zaccarelli M.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19812. doi: 10.7448/IAS.17.4.19812. eCollection 2014.

48.

Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial.

Fabbiani M, Di Giambenedetto S, Quiros-Roldan E, Latini A, Vullo V, Antinori A, Castagna A, Orofino G, Francisci D, Grilli E, Madeddu G, Grima P, Rusconi S, Del Pin B, Mondi A, Borghetti A, Focà E, Colafigli M, De Luca A, Cauda R.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19808. doi: 10.7448/IAS.17.4.19808. eCollection 2014.

49.

Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis.

Zaccarelli M, Fabbiani M, Pinnetti C, Borghi V, Giannetti A, Sterrantino G, Lorenzini P, Latini A, Loiacono L, Colafigli M, Ammassari A, D'Ettorre G, Plazzi M, Di Giambenedetto S, Antinori A.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19802. doi: 10.7448/IAS.17.4.19802. eCollection 2014.

50.

Liver fibrosis is associated with cognitive impairment in HIV-positive patients.

Ciccarelli N, Fabbiani M, Grima P, Limiti S, Fanti I, Mondi A, Gagliardini R, D'Avino A, Borghetti A, Cauda R, Di Giambenedetto S.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19722. doi: 10.7448/IAS.17.4.19722. eCollection 2014.

Supplemental Content

Loading ...
Support Center